PROTACs in Action: Bridging Chemical Biology and Drug Discovery for Protein Degradation
Journal of Medico Informatics · 28.04.2026 · 02 (Issue 02) · 14-22
DOI: 10.64659/jomi/215914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medico Informatics, online erschienen am 28.04.2026. Verfasst von Ramar Vanajothi. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteolysis-targeting chimeras (PROTACs) represent a transformative paradigm in drug discovery, fundamentally altering how we approach protein-targeted therapeutics by harnessing the ubiquitin-proteasome system for selective protein degradation. This comprehensive review examines the evolution of PROTAC technology from its conceptual origins in 2001 to its current clinical validation, with over 30 molecules in various stages of clinical development as of 2024. We explore the mechanistic foundations of PROTAC action, including the catalytic mode of protein degradation that distinguishes event-driven from occupancy-driven pharmacology, and examine the structural design principles governing heterobifunctional architecture, linker optimization, and E3 ligase recruitment strategies. The review analyzes current therapeutic applications across oncology, autoimmune diseases, and neurodegenerative disorders, highlighting the clinical success of compounds like ARV-471 and ARV-110 in Phase III trials. Critical challenges including physicochemical property optimization, resistance mechanisms, and bioavailability limitations are addressed alongside emerging solutions through computational design, artificial intelligence integration, and next-generation platforms including conditional degraders, nano-PROTACs, and expanded E3 ligase recruitment. Recent advances in molecular glue degraders, which represent 66% of FDA-approved degraders, and the development of precision medicine approaches through biomarker-guided therapy are also examined. The review concludes with an assessment of future directions, including E3 ligase repertoire expansion beyond the current focus on CRBN and VHL, targeting of previously undruggable proteins, and the integration of PROTAC technology with combination therapies and precision medicine strategies.
Zitieren
APA
Vanajothi, R. (2026). PROTACs in Action: Bridging Chemical Biology and Drug Discovery for Protein Degradation. Journal of Medico Informatics, 02(Issue 02), 14-22. https://doi.org/10.64659/jomi/215914
Vancouver
Vanajothi R. PROTACs in Action: Bridging Chemical Biology and Drug Discovery for Protein Degradation. Journal of Medico Informatics. 2026;02(Issue 02):14-22. doi:10.64659/jomi/215914
BibTeX
@article{Vanajothi2026,
author = {Vanajothi, Ramar},
title = {PROTACs in Action: Bridging Chemical Biology and Drug Discovery for Protein Degradation},
journal = {Journal of Medico Informatics},
year = {2026},
volume = {02},
number = {Issue 02},
pages = {14--22},
doi = {10.64659/jomi/215914}
}
EUVIMED